Axiom Investors LLC DE Decreases Stock Holdings in Insmed, Inc. $INSM

Key Points

• Axiom Investors LLC DE has reduced its stake in Insmed, Inc. by 4.7%, holding 79,925 shares after selling 3,949 shares during the first quarter.
• Insmed reported a loss of ($1.70) EPS for the last quarter, missing estimates, but its revenue grew by 18.9% compared to the same quarter last year.
• Several notable adjustments in analyst ratings occurred, with price targets for Insmed raised by firms like UBS Group and Morgan Stanley, indicating a generally positive outlook on the stock.

Axiom Investors LLC DE trimmed its position in shares of Insmed, Inc. (NASDAQ:INSM - Free Report) by 4.7% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 79,925 shares of the biopharmaceutical company's stock after selling 3,949 shares during the quarter. Axiom Investors LLC DE's holdings in Insmed were worth $6,097,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in INSM. Vanguard Group Inc. lifted its holdings in shares of Insmed by 0.3% in the first quarter. Vanguard Group Inc. now owns 18,268,122 shares of the biopharmaceutical company's stock valued at $1,393,675,000 after purchasing an additional 49,149 shares in the last quarter. Darwin Global Management Ltd. raised its position in Insmed by 23.5% in the 4th quarter. Darwin Global Management Ltd. now owns 12,960,538 shares of the biopharmaceutical company's stock valued at $894,796,000 after buying an additional 2,463,261 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Insmed by 1.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,923,541 shares of the biopharmaceutical company's stock valued at $985,938,000 after acquiring an additional 219,131 shares in the last quarter. Northern Trust Corp boosted its position in Insmed by 19.9% during the 4th quarter. Northern Trust Corp now owns 1,750,642 shares of the biopharmaceutical company's stock worth $120,864,000 after acquiring an additional 290,678 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Insmed by 3.6% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,602,655 shares of the biopharmaceutical company's stock worth $122,267,000 after acquiring an additional 56,048 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on INSM. Morgan Stanley lifted their price objective on shares of Insmed from $126.00 to $144.00 and gave the company an "equal weight" rating in a research report on Thursday, August 21st. Leerink Partners lifted their target price on Insmed from $100.00 to $115.00 and gave the company an "outperform" rating in a research report on Tuesday, June 10th. Stifel Nicolaus lifted their target price on shares of Insmed from $121.00 to $145.00 and gave the stock a "buy" rating in a research report on Thursday, August 14th. JPMorgan Chase & Co. raised their price objective on Insmed from $111.00 to $135.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 20th. Finally, Citigroup upgraded shares of Insmed to a "buy" rating in a report on Tuesday, June 10th. Sixteen research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, Insmed has an average rating of "Moderate Buy" and a consensus target price of $132.57.

Insmed Stock Up 3.0%

INSM traded up $3.85 during mid-day trading on Tuesday, reaching $132.17. 2,361,548 shares of the stock were exchanged, compared to its average volume of 3,216,250. Insmed, Inc. has a 1 year low of $60.40 and a 1 year high of $133.56. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.33 and a current ratio of 6.68. The stock has a market capitalization of $27.94 billion, a PE ratio of -23.15 and a beta of 0.95. The company has a 50 day moving average price of $108.65 and a two-hundred day moving average price of $86.38.

Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, missing analysts' consensus estimates of ($1.30) by ($0.40). Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The firm had revenue of $107.42 million for the quarter, compared to the consensus estimate of $104.06 million. During the same period in the previous year, the business earned ($1.94) earnings per share. The firm's revenue for the quarter was up 18.9% on a year-over-year basis. Insmed has set its FY 2025 guidance at EPS. As a group, research analysts anticipate that Insmed, Inc. will post -4.56 EPS for the current year.

Insider Buying and Selling

In related news, COO Roger Adsett sold 25,000 shares of Insmed stock in a transaction dated Tuesday, August 19th. The stock was sold at an average price of $127.58, for a total value of $3,189,500.00. Following the completion of the sale, the chief operating officer owned 105,637 shares of the company's stock, valued at approximately $13,477,168.46. This trade represents a 19.14% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Sara Bonstein sold 58,400 shares of the business's stock in a transaction dated Monday, July 21st. The stock was sold at an average price of $102.67, for a total value of $5,995,928.00. Following the transaction, the chief financial officer owned 73,505 shares of the company's stock, valued at approximately $7,546,758.35. The trade was a 44.27% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 539,694 shares of company stock worth $53,144,604 in the last ninety days. Corporate insiders own 3.00% of the company's stock.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.